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Opioid prescriptions for pain and epidemic of 
overdose death: can the dramatic reduction in 
anesthesia mortality serve as an example?
Igor Kissin
Department of Anesthesiology, 
Perioperative and Pain Medicine, 
Brigham and Women’s Hospital, 
Harvard Medical School, Boston, 
MA, USA
Abstract: The annual number of US deaths from prescription-opioid overdose quadrupled 
between 1999 and 2010 and in 2010 alone reached 16,651. Deaths from opioid overdose have 
now surpassed the historic death toll from another drug-related epidemic – anesthesia mortal-
ity. In 1954, Beecher and Todd published reliable data on anesthesia-related mortality in the 
US, estimating the annual number of deaths to be nearly 5,000. Presently anesthesia/anesthet-
ics are reported as the underlying cause in approximately 34 deaths in the US annually. This 
spectacular decline in anesthesia-related mortality could serve as an example for attempts to 
curb the epidemic of opioid overdose death. The main reason that led to the dramatic decline in 
anesthesia-related mortality is the context in which anesthetics are used. It includes training of 
the anesthesia providers, the introduction of specific standards of patient safety, and anesthesia 
monitoring. I suggest that the introduction of a similar multifactorial proper context for the use 
of opioids in the treatment of chronic nonmalignant pain might be the same “game changer” it 
was for safety in anesthesia. 
Keywords: chronic pain, addiction, opioid-use disorder, treatment compliance, apprenticeship, 
metrics of opioid effectiveness, aberrant opioid-related behavior
Introduction
The number of US deaths from prescription-opioid overdose quadrupled between 1999 
and 2010 and in 2010 alone reached 16,651.1 Nevertheless, despite multiple preventive 
actions on many levels, the number of deaths continues to grow. According to some 
estimates, in 2014 the number of all opioid overdose deaths in the US increased to 
28,647.2 The annual opioid death toll cannot be attributed purely to opioids – as the vast 
majority of these cases are found to have other central nervous system depressants in their 
systems.1 Deaths from opioid overdose have now surpassed the historic death toll from 
another drug-related epidemic – anesthesia-related deaths. In 1954, Beecher and Todd3 
published reliable data on anesthesia-related mortality in the US, estimating the num-
ber of deaths to be nearly 5,000 (Table 1). Since then the number of anesthesia-related 
deaths rapidly declined from one in 1,000 anesthesia procedures in the 1940s to one in 
10,000 in the 1970s, and to one in 100,000 in the 1990s and early 2000s.4 Anesthesia/
anesthetics are reported presently4 as the underlying cause in approximately 34 deaths 
in the US annually. Although the differences between these two types of mortalities are 
very profound, the spectacular decline in anesthesia-related mortality could serve as an 
example for attempts to curb the epidemic of opioid overdose death. I suggest that at 
least three factors led to the dramatic decline in anesthesia-related mortality and might 
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be relevant to the fight against the prescription-opioid over-
dose epidemic: 1) focus on the mechanisms underlying high 
mortality that are the most modifiable by preventive actions; 
2) establish apprenticeships for providers; and 3) broaden the 
use of specific monitoring techniques. 
Focus 
One of the best anesthesia-related examples on how to 
focus on the most accessible problems is found in a study 
by Beecher and Todd.3 The authors focused on a sixfold 
increase in anesthesia mortality in patients who received 
a myorelaxant (tubocurarine). This reflected a lack of 
understanding at the time of the pharmacology of neuro-
muscular blockade, especially the residual postoperative 
blockade that impairs the ventilatory drive. The answer 
to this problem came in the form of monitoring. Various 
methods of myorelaxation monitoring were developed, and 
their introduction coincided with a profound reduction in 
anesthesia-related mortality between the pre-1970s and 
the 1970s–1980s. 
Efforts to curb the current epidemic of opioid overdose 
deaths have focused mainly on nonmedical use of opioids; 
a very important aim has been described–opioid addiction 
that occurs in both the medical and nonmedical setting.1 At 
the same time, a key precursor of opioid-related morbidity 
was – and still is – the use of opioids for the treatment of 
chronic nonmalignant pain. The history of opioid consump-
tion confirms the crucial role in this epidemic of the opioid 
treatment of chronic pain. The use of opioids increased gradu-
ally in the second half of the 1980s, began to accelerate in 
the 1990s, and then – has risen precipitously since 2000. This 
coincides with multiple recommendations of various medical 
organizations for more aggressive use of opioids for chronic 
nonmalignant pain.1 Such recommendations appeared since 
1986, when the requirements for evidence-based approaches 
were not yet firmly established. However, there is presently no 
reliable evidence that long-term (>6 months) opioid therapy 
for chronic pain is effective.5–7 In addition to the lack of real 
evidence that the long-term treatment of chronic pain with 
opioids is effective, the addictive nature of opioids was not 
properly exposed. The best illustration for this might be 
a conclusion in a 2006 article on iatrogenic opioid addiction: 
[...] it is not known whether the risk for iatrogenic addiction 
among patients treated with opioids for acute or subacute 
pain is relatively high (>10%) or low (<0.1%).8 
Although the incidence of iatrogenic opioid addiction is 
unknown, opioid use disorders are quite prevalent among 
chronic pain patients. A survey on the lifetime prevalence 
of prescription opioid use disorder among 705 chronic non-
cancer pain patients based on the Diagnostic and Statistical 
Manual of Mental Disorders (DSM)-5 revealed the degree 
of spread of abuse-related behavior – 35% of these patients 
met DSM-5 criteria.9 This indicates that reduction in the use 
of opioids for the treatment of chronic nonmalignant pain 
could profoundly reduce the number of addicted patients. 
The first step to counteract the epidemic should be efforts 
to reduce the number of new patients with chronic non-
malignant pain who are maintained on long-term opioids. 
Addiction has not yet developed at this point, therefore 
reductions should be more significant than from the treat-
ment of addiction (usually requiring life-long efforts). The 
limitation of unnecessary use of opioids for the treatment 
of chronic pain could provide a very significant reduction of 
overdose opioid death rate through prevention of potentially 
addictive treatment. 
Apprenticeship
Due to the relatively small number of pain medicine special-
ists, nonspecialists (mostly primary care providers) are left to 
manage some of the most complex patients with chronic pain. 
The analogous situation in anesthesia is the administration of 
moderate (conscious) sedation by non-anesthesia providers 
when there is the increased risk of morbidity and mortality 
(in such areas as endoscopy, dentistry, etc). To administer 
conscious sedation, a non-anesthesia provider needs a per-
mit that requires more than a didactic course on the topic. 
For example, before it issues a permit to administer dental 
conscious sedation, the Connecticut Department of Public 
Health requires that the applicant (among other more strin-
gent alternatives) have ten documented clinical cases utilizing 
“parenterally administered conscious sedation” (http://www.
ct.gov/dph/cwp/view.asp?a=3121&q+289282). This example 
from anesthesia safe practices implies that long-term (lon-
ger than 6 months) treatment of chronic nonmalignant pain 
should be provided by certified pain medicine specialists; or 
at least physicians who, in addition to the required didactic 
course, completed some type of apprenticeship during which 
they closely interacted for some time with providers who are 
actually practicing adequately controlled treatment. 
Table 1 Estimates of annual number of US deaths: anesthesia vs 
prescription-opioid overdose
Drug-related epidemics 1943–1954 1999–2005
Anesthesia-related deaths 5,1003 344
Prescription-opioid overdose deaths no data 16,651 (2010)15
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Monitoring
Advances in anesthesia monitoring were among the most 
important prerequisites for the dramatic decrease in anesthesia- 
related mortality and morbidity. Improvements were multi-
focused, continuous, and concentrated mostly on prevention 
of adverse cardiovascular and respiratory events.10 Monitoring 
can also be an important factor in the prevention of opioid 
overdose death in the treatment of chronic pain mainly through 
identifying patients who exhibit aberrant drug-related behav-
ior. A number of screening tools have been developed in this 
regard. These tools usually assess correlates of opioid misuse 
such as mood disorder, abuse history, and past behaviors. There 
are also monitoring approaches that directly assess ongoing 
opioid adherence among chronic pain patients, such as the opi-
oid compliance checklist.11 A number of objective indicators of 
prescription-opioid misuse such as periodic urine toxicology 
screens are very reliable. The problem is that most physicians 
providing opioid prescriptions simply do not have enough time 
and experience to properly administer these monitoring tools.11
In addition, it is difficult to monitor the pain-relieving 
effect of opioids, because their benefits in many patients are 
questionable, especially when opioids are used for a long 
time (>6 months). It is possible that the usual metrics of 
analgesic effectiveness, such as pain intensity, might not be 
the best measure of success in chronic pain treatment. Other 
measures of opioid effectiveness that address the suffering 
and disability aspects of chronic pain might be more appro-
priate.12 Monitoring various indices of patient quality of life 
and disability might be of major importance in assessing the 
balance between the risk of aberrant opioid-related behavior 
and the benefits of continuing treatment. 
Conclusion
The main reason for the dramatic decrease in anesthesia-
related mortality is the context in which anesthetics are used. 
It includes training of the anesthesia providers, the introduc-
tion of specific standards of patient safety, and anesthesia 
monitoring.13 As far as this can be used as an example to 
deal with the epidemic of prescription-opioid deaths, only 
the following three factors have been discussed here: 1) focus 
on reduction of the number of new patients with chronic 
nonmalignant pain who are maintained on long-term opioids; 
2) need of an apprenticeship for providers of chronic opioid 
treatment; and 3) close monitoring of chronic nonmalignant 
pain patients for aberrant opioid-related behavior. 
In general, the move from the current situation with opioid 
overdose death requires a multitude of various changes. They 
are best summarized in 12 recommendations of the Centers 
for Disease Control and Prevention (CDC) regarding opioid 
medications for chronic pain.14 On March 15, 2016, the CDC 
released a “Guideline for Prescribing Opioids for Chronic 
Pain” to chart a safer way of using opioids for chronic pain. 
One of the main CDC principals is that non-pharmacologic 
therapy and non-opioid pharmacologic therapy are preferred 
for chronic pain.7 Although prevention of addiction develop-
ment is a great challenge, the opioid addiction treatment is 
an even greater problem. The enormous magnitude of it is 
determined by two factors: treatment of the addiction usu-
ally requires life-long efforts,15 and the number of addicted 
persons is extremely high (may exceed 5 million in the US).1 
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